The ATTRACT Study is a phase 3 clinical study that will measure the effectiveness and safety of an investigational pharmacological chaperone migalastat HCl (AT1001 or GR181413A), when compared to enzyme replacement therapy (ERT) agalsidase, for the treatment of patients with Fabry disease.  

The AT1001-013 study is evaluating the safety and effects of co-administering the investigational pharmacological chaperone migalastat HCl (AT1001 or GR181413A) and the enzyme replacement therapy (ERT) agalsidase in subjects with Fabry disease.